Status:
WITHDRAWN
Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer
Lead Sponsor:
University Hospital, Ghent
Collaborating Sponsors:
Norgine
Conditions:
Breast Cancer
Sentinel Lymph Node
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
A sentinel node procedure is recommended for patients with early stages of breast cancer to exclude metastases to local lymph nodes. This procedure is done with a "tracer" which is injected near to th...
Eligibility Criteria
Inclusion
- Early stage breast cancer (T1, T2)
- Clinically node negative (no enlarged axillary lymph nodes)
Exclusion
- Prior surgery in same breast
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
November 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04487912
Start Date
November 24 2020
End Date
May 1 2021
Last Update
May 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
university hospital, Ghent
Ghent, Belgium